18:12 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves Array's drug combo to treat melanoma

Array BioPharma Inc. (NASDAQ:ARRY) said FDA approved Braftovi encorafenib in combination with Mektovi binimetinib to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. The company said the combo is now available, but declined to provide...
22:04 , Jun 27, 2018 |  BC Extra  |  Company News

FDA approves Array's drug combo to treat melanoma

Array BioPharma Inc. (NASDAQ:ARRY) said FDA approved Braftovi encorafenib in combination with Mektovi binimetinib to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. The company said the combo is now available, but declined to provide...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
16:17 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for binimetinib plus encorafenib in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) reported that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival (OS) compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma....
16:13 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for binimetinib plus encorafenib in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) reported that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival (OS) compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma....
23:56 , Feb 6, 2018 |  BC Extra  |  Clinical News

Array gains on Phase III OS data in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) gained $2.19 (16%) to $16.28 on Tuesday after reporting that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
00:27 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

EMA validates MAA for binimetinib/encorafenib in melanoma

Pierre Fabre Group (Castres, France) said EMA validated an MAA for binimetinib (MEK162) and encorafenib (LGX818) in combination to treat BRAF-mutant advanced, unresectable or metastatic melanoma. The combination is also under FDA review for the...
20:20 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $258.8 million through the sale...
22:12 , Sep 15, 2017 |  BC Extra  |  Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $225 million late Thursday through...